INTRODUCING
iLITE® METABOLIC PANEL

One Platform. Multiple Metabolic Pathways. Smarter Decisions.
Fueling the development of next-generation metabolic therapeutics

As metabolic therapeutics evolve into increasingly complex, multi-target approaches, developers need consistent and flexible tools to investigate drug candidates' biological activity across multiple pathways and modalities.

The ***iLite*® Metabolic Panel** provides a modular set of high-performance cell-based reporter assays specifically designed for the development of next-generation therapeutics for obesity, diabetes, and other metabolic disease.

Built around key incretin and other metabolic targets, the *iLite* Metabolic Panel enables assessment of individual or combinations of targets, generating comparable functional data across pathways to support next-generation multi-agonist development.

NAVIGATING METABOLIC COMPLEXITY

Streamlined Workflow. Accelerated Development.


Built on the same engineered MoA-reflective assay ready cells, enabling direct comparison across assays, for functional characterization and potency testing.

***iLite*® Metabolic Panel**

- *iLite*® GLP-1 Assay Ready Cells
- *iLite*® GIP Assay Ready Cells
- *iLite*® FGF-21 Assay Ready Cells
- *iLite*® Insulin Assay Ready Cells

FASTER TIME-TO-RESULTS WITH THE ASSAY READY CELLS FORMAT

iLite assay ready cells eliminate routine cell maintenance and enable a streamlined workflow from thaw to readout within the same working day.



1 **Thaw & plate** 2 **Add Sample/ Analyte** 3 **Add Detection Reagent** 4 **Measure Luminescence**


Svar Life Science I +46 40 53 76 00 I www.svarlifescience.com

iLite® GLP-1 & GIP Assay Ready Cells


For pathway-specific functional characterization & potency testing of metabolic therapeutics.

ENABLING FUNCTIONAL CHARACTERIZATION ACROSS SINGLE- AND MULTI-AGONISTS

The *iLite*® GLP-1 and GIP Assay Ready Reporter Gene Cell Lines enable sensitive and reproducible assessment of receptor activation by incretin therapeutics. Used individually or in combination, they enable the direct comparison of functional activity of GLP-1, dual GLP-1/GIP, and multi-agonist candidates to support drug discovery and biosimilar characterization.



Agonist	Tirzepatide	Retatrutide	Liraglutide
Hillslope	1.3	1.5	1.3
EC50	758	512	33
Fold induction	126	134	126




Agonist	Tirzepatide	Retatrutide	Liraglutide
Hillslope	2.8	2.8	-
EC50	6.1	7.7	-
Fold induction	107	142	-


Dose-response curves demonstrate receptor-specific activation by Liraglutide (GLP-1R agonist), Tirzepatide (dual GIPR/GLP-1R agonist), and Retatrutide (triple GCGR/GIPR/GLP-1R agonist).

RELIABLE POTENCY ASSESSMENT FOR METABOLIC THERAPEUTICS

The *iLite*® platform enables accurate relative potency assessment of GLP-1 and GIP receptor agonists. The high assay reproducibility and excellent performance support routine lot release testing, comparability studies, biosimilar development, and process development.




Expected linearity	50%	75%	100%	125%	150%	200%
EC50	69	46	34	27	23	17
Accuracy	101%	102%	NA	100%	99%	100%
Hillslope	1.4	1.3	1.4	1.4	1.5	1.1



Expected linearity	50%	75%	100%	125%	150%	200%
EC50	14	9.9	7.2	5.4	4.6	3.3
Accuracy	101%	103%	NA	95%	96%	92%
Hillslope	2.1	2.3	2.5	2.5	2.3	2.5

Excellent linearity ($R^2 \geq 0.998$), accurate relative potency, and consistent curve parallelism data demonstrate robust assay performance.



One Platform. Multiple Pathways. Faster Development Decisions.

Built on Svar Life Science's proprietary *iLite*® dual-reporter technology, the *iLite* Metabolic Panel provides a scalable, biologically relevant solution for functional characterization and potency assessment across today's rapidly evolving metabolic therapeutic landscape.

MECHANISM OF ACTION

The *iLite*® GLP-1 and GIP responsive cell lines translate receptor activation into a quantitative luminescent signal through the Gs/cAMP/CRE-luciferase pathway. This biologically relevant functional readout supports receptor agonist characterization and enables accurate and reproducible relative potency assessment, while Renilla normalization enhances assay robustness and reliability.

Scan QR-code to learn more!

Doc No: S-232-GB00, Sept 2026